Penserra Capital Management LLC Trims Holdings in Natera, Inc. (NASDAQ:NTRA)

Penserra Capital Management LLC cut its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 96.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 566 shares of the medical research company's stock after selling 16,224 shares during the quarter. Penserra Capital Management LLC's holdings in Natera were worth $80,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Fulton Bank N.A. raised its position in shares of Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after acquiring an additional 71 shares during the last quarter. QRG Capital Management Inc. raised its position in shares of Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after acquiring an additional 81 shares during the last quarter. Colonial Trust Co SC raised its position in shares of Natera by 7.8% during the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after acquiring an additional 96 shares during the last quarter. Silvercrest Asset Management Group LLC raised its position in shares of Natera by 3.6% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company's stock worth $445,000 after acquiring an additional 98 shares during the last quarter. Finally, Utah Retirement Systems raised its position in shares of Natera by 1.6% during the fourth quarter. Utah Retirement Systems now owns 6,200 shares of the medical research company's stock worth $981,000 after acquiring an additional 100 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on NTRA shares. UBS Group raised their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Barclays raised their price objective on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Finally, Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Natera has an average rating of "Moderate Buy" and a consensus target price of $184.63.

Natera Stock Down 1.8%

Natera stock traded down $2.93 during mid-day trading on Friday, reaching $160.43. 710,024 shares of the company's stock were exchanged, compared to its average volume of 1,423,140. The business's fifty day simple moving average is $161.05 and its 200 day simple moving average is $158.41. The firm has a market capitalization of $21.91 billion, a PE ratio of -109.14 and a beta of 1.73. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. Natera's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period last year, the company posted ($0.56) earnings per share. On average, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total value of $500,310.00. Following the sale, the insider directly owned 130,205 shares in the company, valued at $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the sale, the director owned 8,118 shares in the company, valued at approximately $1,358,628.48. The trade was a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,272 shares of company stock valued at $8,345,368. Corporate insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.